drugset

drugset / Trial / NCT06118788

Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

NCT06118788 ↗

Phase 1/2 Recruiting 24 enrolled Guangzhou Bio-gene Technology Co., Ltd

NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, single-dose dose-escalation and dose-expansion study.

Timeline

Start: 2024-03-07
Primary completion: 2027-03
Completion: 2027-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BG1805	Unknown	—	Intravenous

Indications